Fundraising FoxvenBio Partners — 2015 Investments
7 investments dated 2015 · listed companies and verified rows first · show all
Precision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).
BiotechDeep TechHealthtechDurham, US
MATTHEW KANE(Executive Officer, Director)Jeff Smith(Co-founder)inDerek Jantz(Co-founder)inTODD MELBY(Executive Officer)inMichael Amoroso(President, Chief Executive Officer)in
Board seatRobert Adelman· per SEC Form D
Co-investorsage1Agent CapitalAliment CapitalBrace PharmaF-Prime CapitalOCV Partners+6 more
ALX Oncology develops therapies for cancer treatment, operating in the biotechnology and medical technology sectors.
BiotechHealthtechMedical Devices
Corey Goodman(Chairman)inJason Lettmann(Chief Executive Officer)in
Co-investorsLightstone Venturesage1Foresite CapitalHBM Healthcare InvestmentsHBM PartnersLogos+1 more
NASDAQ-listed company developing therapies for complement cascade-driven diseases in haematology, ophthalmology, and nephrology.
BiotechCrestwood, US
Pascal Deschatelets(Executive Officer)inCedric Francois(Executive Officer, Director)in
BoardGerald Chan(Director)Stephanie O'Brien(Director)Alec Machiels(Director)A. Sinclair Dunlop(Director)
Board seatRobert Adelman· per SEC Form D
Co-investorsAvoro Capital AdvisorsEMBL VenturesEpidarex CapitalF-Prime CapitalKeyhorse CapitalSofinnova Ventures+1 more
San Diego clinical-stage biopharma developing non-bile acid FXR agonists for liver and gastrointestinal diseases.
BiotechSan Diego, US
Ronald Evans(Director)Trisha Millican(Executive Officer)Ken Song(Executive Officer, Director)
BoardKristina Burow(Director)inRichard Heyman(Director)inAmir Nashat(Director)in
Board seatRobert Adelman· per SEC Form D · $37.8M raise · filed Nov 2016
Co-investorsage1EcoR1 CapitalLAVLifeSci Venture PartnersLilly Asia VenturesNew Enterprise Associates (NEA)+8 more
BiotechSan Francisco, US
Curt Bradshaw(Executive Officer, Director, Promoter)inFrank Muhlenbeck(Mr. Muhlenbeck is a Manager of the Issuer.)
BoardCorey Goodman(Executive Officer, Director, Promoter)inSteven Dowdy(Director)George Rehm(Mr. Rehm is a member of the Board of Managers of the Issuer.)
Board seatRobert Adelman· per SEC Form D · $4M raise · filed Dec 2015
Activating the immune system to recognize and destroy tumor cells.
BiotechCambridge, US
Art Krieg(Executive Officer, Director)Barry Labinger(Executive Officer, Director)Chuck Abdalian(Executive Officer)David Mauro(Executive Officer)Karen Brennan(Executive Officer)Charles Yon(Executive Officer)
Co-investorsDecheng CapitalF-Prime CapitalLongitude CapitalSofinnova VenturesNovo Holdings
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Alexo Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.